Member Info for Dibs61

Where my mouth is and added on this mornings weakness. Both the last two trades are my buys. Next week is a MASSIVE week for us and I want full exposure.

Hmmm what a surprise. Dropping the price on very little volume just before what is likely to be an important announcement. You ain�t having a single one my shares at this price!

Yesterday afternoon this comment was posted on Men and Motors Facebook page: �Are we ready for this. Maybe, fingers crossed and a successful MipCom?� Along with a photo of a bottle of Champagne, bucket and glass! What would you conclude from that? My conclusion is that (hopefully) a broadcasting deal for Men and Motors Is forthcoming.

Big news coming?

They just cannot seem to reduce the debt

Useful incentive for certain key managers within the company to participate and be rewarded for the future substantial growth we will see here.

Once financing uncertainty resolved

Agreed - and yes LM isn't even attempting his usual bullishness. Also explains the persistent lacklustre SP performance. As I say, the SP always tells you a story!

@ 4.5/5p? SP action has all the hallmarks. Even though they said they had cash coming in at end of month maybe its not enough�..

And one tiny sell�. and it goes down.

The company never announces it will issue a trading update in advance. But they always announce a trading update in the 2nd half of October. There is no reason to believe this year will be any different. When I said 'imminent' I meant in the next week or so.

Bearly alive today.... Likely this kind of stock very interest rate sensitive. Also to matters of the general state of economy, perceptions etc Irony is I agree it looks cheap on financials/fundamentals but vulnerable to negative economic sentiment or just market sentiment in general. Also it has had a big push up over last few months so plenty will have bought a lot cheaper and not want to lose their profit. Nervous market.

I am a little puzzled why this deal was announced? It's a bit unlike ODX to make stand alone announcements on deals - and this could easily be incorporated into the imminent trading update. Don't get me wrong, it's def positive and will likely be accretive over time but just not like them as typically this would normally be in the small print of a trading update!

The first objective of the fundraising in late June was, and I quote: "1. Increase FoodPrint� traction in the USA by increasing sales and marketing resource, developing product enhancements that meet the US lab environment and investing into more automated manufacturing capacity." Big Tick in the box then ✅

And if I can pick up any around the placing price that's my target now.

They will also require WHO prerequisite for large tender orders but I reckon that's a given since they already have good links with WHO and there is a pressing need for these tests. Not long to go now. Update should be next week. Amazed that there is so little interest. So under the radar of investors. All you have to do is a bit of research and figure it out.

ODX posted this tweet today along with a picture of a clinical/lab assistant training with Visitect CD4. 😊👍🏻 "We've been in #Johannesburg training. We believe in bringing robust #RDTs to market & providing ample #training to build user confidence." Note the use of the word 'training' NOT testing ;) wakey wakey market Visitect CD4 is coming

Nw is that you buying this lunchtime Omerta?

Hi boom, Interesting. Only just got round to reading that RNS. Raised the eyebrows somewhat.

Hi Omert� and welcome. Good to have a fresh contribution on this board. I'll try not to waffle in response. Yes it does look as if Mills could've been behind last months rise as the size of the trades were likely institutional. I wouldn't say CD4 is of paramount importance. It will be transformational when it happens but we already have a solid profitable growing business here without it. In terms of my expectations for the upcoming trading update. I hope to see continued growth across all LOB's. I would like to see more progress in their various projects (particularly Visitect CD4) but also other RDT's. In terms of your last question - diversification is key - given this is such a small company it's still something of a global business so various types of cultural, political risk are spread. They already operate in many stable regions successfully and are now spreading into Africa (as you may have seen). Financially they keep a tight control on costs, are cash generative and reinvest their profits back into the business. Basically what I like is that you have the buffer of a solid good quality profitable business with a range of products but the blue sky opportunities (for example Visitect CD, Allersys etc) in for free. This imo is an undervalued company I would obviously recommend the corporate website but also the Hardman reports. Most importantly though DYOR. HTH